117 related articles for article (PubMed ID: 34628891)
1. Multiple blood parameters may serve as a warning to immunochemotherapy-related interstitial lung disease in B-cell lymphoma.
Xia F; Liu H; Zhang H; Ping N; Wang P; Jin Z; Zhu J; Qu C
Ann Palliat Med; 2021 Sep; 10(9):9660-9668. PubMed ID: 34628891
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.
Liu C; Zhang X; Zhu Y; Wei J; Ye X; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Ann Hematol; 2023 Sep; 102(9):2387-2395. PubMed ID: 37278748
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of pneumocystis pneumonia in interstitial lung disease: a retrospective study.
Liu L; Ji T; Chen R; Fan L; Dai J; Qiu Y
Infection; 2024 Jun; 52(3):985-993. PubMed ID: 38147199
[TBL] [Abstract][Full Text] [Related]
4. [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].
Shimizu R; Sakemura R; Iwata S; Hayakawa H; Miyao K; Kajiguchi T
Rinsho Ketsueki; 2019; 60(5):365-371. PubMed ID: 31167996
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
7. Non-infectious pulmonary toxicity of rituximab: a systematic review.
Hadjinicolaou AV; Nisar MK; Parfrey H; Chilvers ER; Ostör AJ
Rheumatology (Oxford); 2012 Apr; 51(4):653-62. PubMed ID: 22157468
[TBL] [Abstract][Full Text] [Related]
8. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
9. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease during trimethoprim/sulfamethoxazole administration.
Yuzurio S; Horita N; Shiota Y; Kanehiro A; Tanimoto M
Acta Med Okayama; 2010 Jun; 64(3):181-7. PubMed ID: 20596129
[TBL] [Abstract][Full Text] [Related]
12. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
Md Yusof MY; Kabia A; Darby M; Lettieri G; Beirne P; Vital EM; Dass S; Emery P
Rheumatology (Oxford); 2017 Aug; 56(8):1348-1357. PubMed ID: 28444364
[TBL] [Abstract][Full Text] [Related]
13. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
Ge Y; Li S; Tian X; He L; Lu X; Wang G
Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients.
Lang M; Yu J; Wang X; Song Z; Li L; Qiu L; Zhang H
Hematol Oncol; 2018 Dec; 36(5):779-785. PubMed ID: 30144117
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
Doyle TJ; Dhillon N; Madan R; Cabral F; Fletcher EA; Koontz DC; Aggarwal R; Osorio JC; Rosas IO; Oddis CV; Dellaripa PF
J Rheumatol; 2018 Jun; 45(6):841-850. PubMed ID: 29606668
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review.
Bellan M; Patrucco F; Barone-Adesi F; Gavelli F; Castello LM; Nerviani A; Andreoli L; Cavagna L; Pirisi M; Sainaghi PP
Autoimmun Rev; 2020 Feb; 19(2):102453. PubMed ID: 31838163
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.
Park SY; Kim MY; Choi WJ; Yoon DH; Lee SO; Choi SH; Kim YS; Suh C; Woo JH; Kim SH
Med Mycol; 2017 Jun; 55(4):349-357. PubMed ID: 28339533
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study.
Langlois V; Gillibert A; Uzunhan Y; Chabi ML; Hachulla E; Landon-Cardinal O; Mariampillai K; Champtiaux N; Nunes H; Benveniste O; Hervier B
J Rheumatol; 2020 Nov; 47(11):1678-1686. PubMed ID: 32173654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
